BioSpace News Archive

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data supporting its lead clinical oncology program, RTX-240, at the upcoming Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting. The meeting is being held virtually from Novem

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Premal Patel, M.D., Ph.D., as chief medical officer.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of October 2020, which is payable on November 16, 2020 to shareholders of record at the close of business on October 30, 2020.

Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Given the pending transaction with Teladoc Health, Livongo is not hosting a conference call in conjunction with its third quarter of 2020 earnings release. About Livongo Livongo empowers people with chronic conditions to live better and healthi

Proprietary and differentiated Transport Vehicle (TV) technology shows potential to solve the BBB challenge by delivering biotherapeutics to the brain New preclinical data support the potential for systemic administration of ETV:IDS (DNL310) to treat the neurological pathology of Hunter syndrome and replace standard-of-care therapy Early safety and biomarker data from ongoing Phase 1/2 trial of DNL310 expected by year end 2020 and, if positive, these data would validate Denali’s TV technology

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13 th Clinical Trials on Alzheimer’s Disease (CTAD) digital event, and the American Heart Association (AHA) Scientific Sessions virtual experience, featuring OnDemand oral presentations on apabetalone. Through participation at le

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary

Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading provider of advanced veterinary diagnostic and specialty products, plans to report its third quarter 2020 financial performance in a press release before the market opens on Thursday, November 5, 2020 and to host an earnings call to discuss the results followi

entrinsic bioscience (EBS) , a company pioneering a next generation protein modulation technology, today announced that it has been granted U.S. Patent No. (USPN) 10,758,507 (‘507 patent) for novel therapeu

- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2020 financial results and provide an update on the company’s business and outlook on Thursday, October 29, 2020 at 4:30 p.m. (ET) after the closing of the market. The call can be acc